COMMUNIQUÉS West-GlobeNewswire

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

13/03/2025 - 23:07

○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD granted by the [...]

Cellectis publie ses résultats financiers du quatrième trimestre 2024 et de l’exercice 2024 et une mise à jour de ses activités

13/03/2025 - 23:46

○ UCART22 : présentation des données de Phase 1 et de la stratégie de développement prévues au troisième trimestre 2025. Statuts de médicament orphelin et de médicament pour une maladie pédiatrique rare accordés par la [...]

Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States

14/03/2025 - 00:42

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil ® is [...]

Pineapple Inc. Provides Shareholder Update and 2025 Outlook

14/03/2025 - 01:00

Company Expands into Cannabis Business Management and Functional Mushroom Markets to Drive Growth and Profitability LOS ANGELES, CA, March 13, 2025 (GLOBE NEWSWIRE) -- Pineapple, Inc. (OTC: PNPL) (“Pineapple” or the “ [...]

Guthrie Launches Maternity Oasis Mobile (MOM) Unit

14/03/2025 - 03:37

Please note a correction in the earlier news release. We do not provide contraception on the Maternity Oasis Mobile Unit. If you have indicated this in any of your coverage, we kindly ask that you remove it. BINGHAMTON [...]

Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia

14/03/2025 - 07:00

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia and nocturia In [...]

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

14/03/2025 - 07:15

Allschwil, Switzerland, March 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Avextra Showcases Study Findings on World Sleep Day 2025

14/03/2025 - 10:52

Cannabis-Based Therapy Shows Promise in Improving Sleep Quality and Pain Management Bensheim, Germany – 14 March 2025 – In anticipation of World Sleep Day, Avextra has revealed findings from its IMPACT study at the [...]

Coloplast Finance B.V. - Decisions at the Annual General Meeting

14/03/2025 - 11:25

On 14 March 2025, Coloplast Finance B.V. held its Annual General Meeting. At the Annual General Meeting, the sole shareholder, Coloplast A/S, approved the annual report for the financial year 2023/24. In addition, Ernst [...]

ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label

14/03/2025 - 11:50

ILUVIEN now approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in addition to diabetic macular edema (DME) ANI plans to begin marketing ILUVIEN in the U.S. [...]

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

14/03/2025 - 11:50

- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE [...]

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

14/03/2025 - 12:00

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]

Iridex Comments on Recent Stock Price Volatility

14/03/2025 - 12:00

MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of [...]

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

14/03/2025 - 12:45

Interim Analysis Expected End of 2Q 2025 BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery [...]

Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

14/03/2025 - 13:00

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report [...]

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

14/03/2025 - 13:00

SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

14/03/2025 - 13:00

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious [...]

ORYZON to Provide Corporate Progress Updates at Several Events in March-April

14/03/2025 - 13:00

BIO-Europe Spring 2025 Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

14/03/2025 - 13:00

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for [...]